Article
Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.
American journal of respiratory and critical care medicine - 1 Mar 2017
Chang I-Shou, Jiang Shih Sheng, Yang James Chih-Hsin, Su Wu-Chou, Chien Li-Hsin, Hsiao Chin-Fu, Lee Jih-Hsiang, Chen Chih-Yi, Chen Chung-Hsing, Chang Gee-Chen, Wang Zhaoming, Lo Fang-Yi, Chen Kuan-Yu, Wang Wen-Chang, Chen Yuh-Min, Huang Ming-Shyan, Tsai Ying-Huang, Su Yu-Chun, Hsieh Wan-Shan, Shih Wen-Chi, Shieh Shwn-Huey, Yang Tsung-Ying, Lan Qing, Rothman Nathaniel, Chen Chien-Jen, Chanock Stephen J, Yang Pan-Chyr, Hsiung Chao A
Abstract excerpt
RATIONALE: Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR-tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemotherapy. However, many patients with advanced NSCLC who have mutated EGFR do not respond to first-line EGFR-TKI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.